Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been mixed. Over the last four quarters, the company has beaten estimates on two occasions. Overall, Alexion has posted an average positive earnings surprise of 3.12% for the four trailing quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion missed on earnings expectations. Our consensus called for EPS of $1.04, and the company reported EPS of $1.03 (these figures include stock-based compensation expense).
Revenue: Revenues were above expectations. Alexion posted revenues of $799 million, compared to our consensus estimate of $784.1million.
Key Stats: Soliris continues to drive revenues at Alexion. Strensiq and Kanuma sales are also picking up to global launches.
2016 Guidance: The company has revised its 2016 outlook. The company now expects adjusted earnings per share to be at the upper end of the previously guided range of $4.50 to $4.65. Also, the company now expects revenues to be at the upper end of previously guided range of $3.05 to $3.10 billion.
Check back later for our full write up on this Alexion earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Image: Bigstock
Alexion (ALXN) Misses on Q2 Earnings, Beats Revenues
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been mixed. Over the last four quarters, the company has beaten estimates on two occasions. Overall, Alexion has posted an average positive earnings surprise of 3.12% for the four trailing quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion missed on earnings expectations. Our consensus called for EPS of $1.04, and the company reported EPS of $1.03 (these figures include stock-based compensation expense).
Revenue: Revenues were above expectations. Alexion posted revenues of $799 million, compared to our consensus estimate of $784.1million.
Key Stats: Soliris continues to drive revenues at Alexion. Strensiq and Kanuma sales are also picking up to global launches.
2016 Guidance: The company has revised its 2016 outlook. The company now expects adjusted earnings per share to be at the upper end of the previously guided range of $4.50 to $4.65. Also, the company now expects revenues to be at the upper end of previously guided range of $3.05 to $3.10 billion.
ALEXION PHARMA Price
ALEXION PHARMA Price | ALEXION PHARMA Quote
Check back later for our full write up on this Alexion earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>